Stockscreener 앱 받기
1.09
1.87%
0.02
시간 외 거래:
1.07
-0.02
-1.83%
전일 마감가:
$1.07
열려 있는:
$1.06
하루 거래량:
1.78M
Relative Volume:
0.51
시가총액:
$396.10M
수익:
$1.21M
순이익/손실:
$-177.12M
주가수익비율:
-1.3625
EPS:
-0.8
순현금흐름:
$-162.37M
1주 성능:
-0.91%
1개월 성능:
+3.81%
6개월 성능:
+224.40%
1년 성능:
-32.72%
1일 변동 폭
$1.05
$1.11
1주일 범위
$1.03
$1.20
52주 변동 폭
$0.2836
$2.175
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
LXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.09 | 388.84M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Can trapped investors hope for a rebound in Lexicon Pharmaceuticals Inc.Profit Target & Verified Stock Trade Ideas - Newser
Price action breakdown for Lexicon Pharmaceuticals Inc.2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
What is Lexicon Pharmaceuticals Inc.’s valuation compared to sectorDividend Hike & Low Drawdown Investment Ideas - خودرو بانک
Using Python tools to backtest Lexicon Pharmaceuticals Inc. strategies2025 Big Picture & Safe Capital Growth Tips - Newser
What’s the MACD signal for Lexicon Pharmaceuticals Inc.Weekly Market Outlook & Short-Term High Return Ideas - خودرو بانک
Can Lexicon Pharmaceuticals Inc. ride the EV waveOil Prices & Safe Capital Growth Stock Tips - خودرو بانک
How to build a dashboard for Lexicon Pharmaceuticals Inc. stockJuly 2025 Sector Moves & Short-Term High Return Ideas - Newser
Is Lexicon Pharmaceuticals Inc. meeting your algorithmic filter criteriaJuly 2025 Summary & Trade Opportunity Analysis Reports - Newser
Heatmap analysis for Lexicon Pharmaceuticals Inc. and competitors2025 Price Action Summary & High Return Trade Guides - Newser
How to escape a deep drawdown in Lexicon Pharmaceuticals Inc.2025 Trading Volume Trends & Safe Entry Trade Reports - Newser
Using portfolio simulators with Lexicon Pharmaceuticals Inc. includedQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - Newser
Will Lexicon Pharmaceuticals Inc. continue its uptrendGap Up & Weekly Setup with High ROI Potential - Newser
What is Lexicon Pharmaceuticals Inc.’s TAM (Total Addressable Market)2025 Price Targets & Verified Swing Trading Watchlists - خودرو بانک
Lexicon Pharmaceuticals' (LXRX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 - Yahoo Finance
Top chart patterns to watch in Lexicon Pharmaceuticals Inc.Portfolio Gains Summary & Free Expert Verified Stock Movement Alerts - Newser
Combining price and volume data for Lexicon Pharmaceuticals Inc.Exit Point & Risk Controlled Swing Alerts - Newser
What is Lexicon Pharmaceuticals Inc.’s book value per shareJuly 2025 Review & Expert Verified Stock Movement Alerts - خودرو بانک
Analyzing net buyer seller activity in Lexicon Pharmaceuticals Inc.Quarterly Trade Report & Daily Market Momentum Tracking - Newser
Lexicon Pharmaceuticals Inc. stock momentum explainedCPI Data & Daily Profit Maximizing Tips - Newser
Lexicon Pharmaceuticals' Strategic R&D Pivots and Licensing Catalysts in 2025 - AInvest
Lexicon Pharmaceuticals' Strategic Positioning in the Biopharma Sector - AInvest
Can Lexicon Pharmaceuticals Inc. generate free cash flow2025 Valuation Update & Weekly High Conviction Ideas - خودرو بانک
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 - The Manila Times
Lexicon Pharmaceuticals to Present Patient Insights on Diabetic Peripheral Neuropathic Pain at PAINWeek 2025 - Quiver Quantitative
30% of Diabetics Suffer Neuropathic Pain: Lexicon Study Reveals Impact on Daily Life at PAINWeek - Stock Titan
H.C. Wainwright reiterates Buy rating on Lexicon Pharmaceuticals stock at $4 - Investing.com Canada
How to use a screener to detect Lexicon Pharmaceuticals Inc. breakouts2025 Performance Recap & High Accuracy Trade Alerts - Newser
Pattern recognition hints at Lexicon Pharmaceuticals Inc. upsideMarket Sentiment Report & Real-Time Chart Pattern Alerts - Newser
Update Recap: Can Lexicon Pharmaceuticals Inc. reach all time highs this year2025 Valuation Update & Real-Time Market Trend Scan - خودرو بانک
Buybacks Report: What’s the MACD signal for Lexicon Pharmaceuticals Inc.Market Volume Summary & Technical Entry and Exit Alerts - خودرو بانک
Lexicon Pharmaceuticals: HC Wainwright raises Buy rating, PT to $4. - AInvest
28% Heart Failure Risk Reduction: Lexicon's Sotagliflozin Proves Equally Effective in Elderly Patients Over 75 - Stock Titan
Ideas Watch: Is Lexicon Pharmaceuticals Inc. benefiting from innovation trendsJuly 2025 Market Mood & Community Trade Idea Sharing Platform - خودرو بانک
Analysts Backtest Strategies on Lexicon Pharmaceuticals Inc. With Promising Results getLinesFromResByArray error: size == 0 - kangso.co.kr
What’s the RSI of Lexicon Pharmaceuticals Inc. stockQuarterly Profit Report & Real-Time Buy Zone Alerts - خودرو بانک
MACD Cross Could Confirm Trend in Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & Target Return Focused Stock Picks - beatles.ru
Visual analytics tools that track Lexicon Pharmaceuticals Inc. performanceMarket Growth Report & Fast Momentum Stock Entry Tips - Newser
Measuring Lexicon Pharmaceuticals Inc.’s beta against major indices2025 Buyback Activity & Reliable Momentum Entry Alerts - Newser
Should you hold or exit Lexicon Pharmaceuticals Inc. nowJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - Newser
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):